Duality Advisers, LP Exelixis, Inc. Transaction History

Duality Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$14.96 - $17.39 $18,894 - $21,963	1,263 Added 1.2%	106,853 $1.71 Million
Q3 2022 Nov 03, 2022	BUY	$15.68 - $22.27 $1.66 Million - $2.35 Million	105,590 New	105,590 $1.66 Million
Q3 2021 Nov 08, 2021	SELL	$16.3 - $21.14 $3.88 Million - $5.03 Million	-237,968 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$17.95 - $25.56 $4.27 Million - $6.08 Million	237,968 New	237,968 $4.34 Million
Q1 2021 May 13, 2021	SELL	$20.53 - $25.22 $1.48 Million - $1.82 Million	-72,022 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$18.39 - $24.8 $1.32 Million - $1.79 Million	72,022 New	72,022 $1.45 Million
Q3 2020 Nov 12, 2020	SELL	$20.67 - $26.94 $1.89 Million - $2.46 Million	-91,199 Closed	0 $0
Q2 2020 Jul 29, 2020	BUY	$16.46 - $27.42 $1.5 Million - $2.5 Million	91,199 New	91,199 $2.17 Million
Q1 2020 May 06, 2020	SELL	$14.46 - $21.8 $1.1 Million - $1.66 Million	-75,939 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$15.15 - $18.89 $258,625 - $322,471	-17,071 Reduced 18.35%	75,939 $1.34 Million
Q3 2019 Nov 08, 2019	BUY	$17.68 - $22.65 $1.64 Million - $2.11 Million	93,010 New	93,010 $1.65 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.